title: In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells.
abstract: Ether lipid analogues of platelet-activating factor (1-octadecyl-2-acetyl-sn-glycero-3-phosphocholine) possess a wide range of biological activities, including inhibition of neoplastic cell growth in vitro and in vivo. This activity is believed to be membrane mediated. Three different ether lipid analogues, 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine, 1-thiohexadecyl-2-ethyl-rac-glycero-3-phosphocholine, and 4-amino-methyl-1-[2,3-(di-n-decyloxy)-n-propyl]-4-phenylpiperidine , were combined with three DNA-interactive drugs, Adriamycin, 4-hydroperoxycyclophosphamide, and cisplatin, in the expectation that combinations of drugs with different mechanisms of action might show enhanced antitumor activity. The in vitro antiproliferative activity of the combinations was measured with a semisoft agarose clonogenic assay of an ovarian adenocarcinoma cell line. Various permutations of drug combinations were studied. Isobologram analyses and different treatment schedules were performed. Enhanced antiproliferative activity was found with combinations of ether lipids with DNA-interactive drugs in comparison with single agents. Statistical evaluation of the data indicated that the increase in activity was due to an additivity phenomenon. Neither synergism nor antagonism was found.
authors.affiliation: Department of Biochemistry, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.
authors.forename: A
authors.initials: A
authors.lastname: Noseda
authors.forename: M E
authors.initials: ME
authors.lastname: Berens
authors.forename: J G
authors.initials: JG
authors.lastname: White
authors.forename: E J
authors.initials: EJ
authors.lastname: Modest
mesh_terms: D000230:Adenocarcinoma; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002455:Cell Division / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D066298:In Vitro Techniques; D010051:Ovarian Neoplasms; D010742:Phospholipid Ethers / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D010742:Phospholipid Ethers; D010880:Piperidines; C055271:1-thiohexadecyl-2-ethyl-glycero-3-phosphocholine; C026659:edelfosine; C038408:CP 46665; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; C011272:perfosfamide